3/21
08:41 am
brns
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.